Sign in

CIK 0002088082

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Electra Therapeutics, Inc.

Sign in to watch
Ticker
ETRA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
832193635
Phone
+1 888-743-2290
Business address
230 EAST GRAND AVENUE, SUITE S-100, SOUTH SAN FRANCISCO, CA, 94080
  1. SCHEDULE 13G Stake Statement of Beneficial Ownership
  2. 10-Q Report Quarterly Report
  3. 8-K Event Results of operations
  4. 4 Open-market buy Director bought 92,116 shares at an average $8.08 ($744,531)
  5. 4 Open-market buy Director bought 92,116 shares at an average $8.08 ($744,531)
  6. 4 Open-market buy Director bought 472,571 shares at an average $7.63 ($3,605,116)
  7. 4 Open-market buy Director bought 472,571 shares at an average $7.63 ($3,605,116)
  8. SCHEDULE 13G Stake Statement of Beneficial Ownership
  9. SCHEDULE 13G Stake Statement of Beneficial Ownership
  10. SCHEDULE 13G Stake Statement of Beneficial Ownership
  11. SCHEDULE 13D Stake Beneficial Ownership Report
  12. 4 Open-market buy Director bought 1,333,333 shares at $15.00 ($19,999,995)
  13. 4 Open-market buy Director bought 1,333,333 shares at $15.00 ($19,999,995)
  14. 3 Insider Initial Statement of Ownership
  15. 4 Conversion Chief Technical Officer acquired 63,656 shares (conversion)
  16. 4 Conversion Director acquired 255,635 shares (conversion)
  17. 4 Conversion Chief Scientific Officer acquired 85,504 shares (conversion)
  18. 4 Conversion President & CEO acquired 455,484 shares (conversion)
  19. S-8 Other Securities Offered to Employees in Benefit Plans
  20. 8-K Event Bylaws or fiscal year change · Other events

Page 1 of 3 · 41 filings